Eris Lifesciences Limited (NSE:ERIS)
1,620.90
-7.50 (-0.46%)
Oct 29, 2025, 9:30 AM IST
Eris Lifesciences Revenue
Eris Lifesciences had revenue of 7.72B INR in the quarter ending June 30, 2025, with 7.82% growth. This brings the company's revenue in the last twelve months to 29.35B, up 30.64% year-over-year. In the fiscal year ending March 31, 2025, Eris Lifesciences had annual revenue of 28.79B with 44.59% growth.
Revenue (ttm)
29.35B
Revenue Growth
+30.64%
P/S Ratio
7.56
Revenue / Employee
8.75M
Employees
3,354
Market Cap
221.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 28.79B | 8.88B | 44.59% |
| Mar 31, 2024 | 19.91B | 3.29B | 19.83% |
| Mar 31, 2023 | 16.62B | 3.36B | 25.31% |
| Mar 31, 2022 | 13.26B | 1.34B | 11.20% |
| Mar 31, 2021 | 11.93B | 1.34B | 12.71% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 274.80B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Eris Lifesciences News
- 2 months ago - Eris Lifesciences secures ANVISA approval for Ahmedabad sterile injectable facility - Business Upturn
- 2 months ago - Eris Lifesciences secures approval from ANVISA for Ahmedabad facility - Business Upturn
- 3 months ago - Eris Lifesciences shares plunge nearly 5% today despite 41% jump in Q1 net profit - Business Upturn
- 3 months ago - Eris Lifesciences Q1 Results: Net profit jump 41.7% YoY to Rs 118 crore, revenue up 7.8% YoY - Business Upturn
- 5 months ago - Eris Lifesciences shares jump 3% as Q4 EBITDA rises 69.8% YoY to 252.2 crore - Business Upturn
- 6 months ago - Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report - Business Upturn
- 6 months ago - Eris Lifesciences shares surge over 4% as Novo Nordisk reportedly exits Human Mixtard insulin market in India - Business Upturn
- 9 months ago - Eris Lifesciences shares drop 4% as net profit dips 14.3% YoY in Q3 - Business Upturn